tirzepatide week 3 Weeks on with WeightCare! The SURMOUNT-MAINTAIN Phase 3b trial
Description
Tesamorelin typically produces measurable visceral fat reduction over 12 to 26 weeks of consistent therapy, with the Phase III trial data showing 15 percent reduction at 26 weeks
A total of 1,145 patients were randomized
Your weight loss gets the attention, but these metabolic shifts are what reduce long-term cardiovascular and disease risk
This information is intended for your private use only
One helpful program is the Medicare Savings Programs
Even though your appetite is reduced, eating something small every 3-4 hours keeps your system balanced
